R1	AND Arg1:T3 Arg2:T2	
*	OR T9 T8
R2	Has_temporal Arg1:T5 Arg2:T7	
R3	Has_qualifier Arg1:T5 Arg2:T9	
R4	Has_index Arg1:T16 Arg2:T17	
R5	Has_temporal Arg1:T15 Arg2:T16	
R6	Has_temporal Arg1:T13 Arg2:T14	
*	OR T13 T15 T18
R7	Has_negation Arg1:T18 Arg2:T20	
R8	Has_qualifier Arg1:T18 Arg2:T19	
R9	AND Arg1:T21 Arg2:T23	
R10	AND Arg1:T18 Arg2:T21	
R11	AND Arg1:T26 Arg2:T25	
R12	Has_qualifier Arg1:T24 Arg2:T26	
R13	Has_qualifier Arg1:T27 Arg2:T29	
R14	Has_value Arg1:T27 Arg2:T28	
R15	Has_value Arg1:T31 Arg2:T32	
R16	Subsumes Arg1:T30 Arg2:T31	
R17	Has_value Arg1:T34 Arg2:T35	
R18	AND Arg1:T33 Arg2:T34	
*	OR T27 T33 T30
R19	Has_value Arg1:T36 Arg2:T37	
*	OR T40 T41
R20	Has_index Arg1:T44 Arg2:T45	
R21	Has_temporal Arg1:T43 Arg2:T44	
R22	Has_temporal Arg1:T47 Arg2:T48	
R23	Has_temporal Arg1:T49 Arg2:T50	
R24	AND Arg1:T51 Arg2:T52	
R25	AND Arg1:T55 Arg2:T54	
*	OR T47 T51 T49 T55
R26	Has_qualifier Arg1:T56 Arg2:T57	
*	OR T58 T59 T56
R27	Has_negation Arg1:T64 Arg2:T65	
R28	AND Arg1:T63 Arg2:T64	
R29	AND Arg1:T66 Arg2:T67	
R30	Has_qualifier Arg1:T63 Arg2:T66	
*	OR T71 T72 T73
R31	AND Arg1:T74 Arg2:T75	
R32	AND Arg1:T76 Arg2:T77	
*	OR T74 T76
R33	Has_temporal Arg1:T79 Arg2:T80	
R34	Has_temporal Arg1:T81 Arg2:T82	
R35	AND Arg1:T83 Arg2:T78	
R36	Has_qualifier Arg1:T81 Arg2:T83	
*	OR T81 T79
R37	Has_qualifier Arg1:T84 Arg2:T86	
R38	Has_temporal Arg1:T91 Arg2:T90	
*	OR T88 T89
R39	AND Arg1:T87 Arg2:T88	
R40	Has_qualifier Arg1:T87 Arg2:T91	
R41	Has_qualifier Arg1:T87 Arg2:T94	
R42	Has_qualifier Arg1:T87 Arg2:T93	
R43	Has_temporal Arg1:T100 Arg2:T101	
R44	AND Arg1:T105 Arg2:T102	
R45	AND Arg1:T104 Arg2:T100	
*	OR T104 T105
R46	Has_qualifier Arg1:T99 Arg2:T104	
R47	Has_multiplier Arg1:T108 Arg2:T107	
R48	Has_multiplier Arg1:T109 Arg2:T110	
R49	Has_multiplier Arg1:T111 Arg2:T112	
R50	Has_multiplier Arg1:T113 Arg2:T114	
R51	Has_multiplier Arg1:T115 Arg2:T116	
*	OR T113 T115
*	OR T109 T111
R52	Has_multiplier Arg1:T113 Arg2:T118	
R53	Has_multiplier Arg1:T109 Arg2:T117	
R54	Subsumes Arg1:T108 Arg2:T109	
R55	AND Arg1:T123 Arg2:T121	
R56	AND Arg1:T124 Arg2:T122	
*	OR T123 T124
*	OR T126 T127 T128
R57	Has_temporal Arg1:T126 Arg2:T125	
R58	Subsumes Arg1:T123 Arg2:T126	
R59	Has_index Arg1:T132 Arg2:T133	
R60	Has_temporal Arg1:T131 Arg2:T132	
T1	Procedure 6 49	systemic therapy targeting PD-1: PD-L1 axis
T2	Procedure 80 121	conventional multidisciplinary management
T3	Qualifier 69 76	curable
T4	Context_Error 69 76	curable
T5	Condition 176 191	medical disease
T6	Undefined_semantics 176 191	medical disease
T7	Temporal 165 175	concurrent
T8	Qualifier 152 164	uncontrolled
T9	Qualifier 138 144	severe
T11	Subjective_judgement 197 231	in the opinion of the investigator
T12	Non-query-able 124 313	Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol.
T13	Procedure 342 365	wide field radiotherapy
T14	Temporal 366 375	â‰¤ 4 weeks
T15	Procedure 379 417	limited field radiation for palliation
T16	Temporal 418 446	< 2 weeks prior to screening
T17	Reference_point 437 446	screening
T18	Condition 463 472	recovered
T19	Qualifier 473 483	adequately
T20	Negation 459 462	not
T21	Condition 489 517	side effects of such therapy
T22	Undefined_semantics 489 517	side effects of such therapy
T23	Procedure 505 517	such therapy
T24	Condition 545 555	infections
T25	Procedure 566 573	therapy
T26	Qualifier 556 573	requiring therapy
T27	Measurement 619 653	Human Immunodeficiency Virus (HIV)
T28	Value 606 614	positive
T29	Qualifier 655 673	HIV 1/2 antibodies
T30	Condition 676 694	active Hepatitis B
T31	Measurement 696 701	HBsAg
T32	Value 702 710	reactive
T33	Condition 716 727	Hepatitis C
T34	Measurement 729 750	HCV RNA [qualitative]
T35	Value 754 762	detected
T36	Measurement 788 808	Hepatitis C antibody
T37	Value 779 787	negative
T38	Non-query-able 765 841	patients with negative Hepatitis C antibody testing may not need RNA testing
T39	Not_a_criteria 765 841	patients with negative Hepatitis C antibody testing may not need RNA testing
T40	Condition 871 882;902 910	psychiatric disorder
T41	Condition 886 910	substance abuse disorder
T42	Subjective_judgement 844 984	Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
T43	Procedure 1008 1038	systemic anti-cancer treatment
T44	Temporal 1039 1076	prior to the first dose of study drug
T45	Reference_point 1048 1076	the first dose of study drug
T46	Parsing_Error 986 1110	Patients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames:
T47	Condition 1133 1151	autoimmune disease
T48	Temporal 1126 1132	active
T49	Condition 1179 1197	autoimmune disease
T50	Temporal 1168 1175	history
T51	Condition 1201 1241	syndrome that requires systemic steroids
T52	Drug 1224 1241	systemic steroids
T53	Undefined_semantics 1201 1241	syndrome that requires systemic steroids
T54	Drug 1245 1269	immunosuppressive agents
T55	Condition 1201 1223;1245 1269	syndrome that requires immunosuppressive agents
T56	Condition 1306 1322	childhood asthma
T57	Qualifier 1297 1305	resolved
T58	Condition 1285 1293	vitiligo
T59	Condition 1323 1328	atopy
T61	Not_a_criteria 1271 1361	Patients with vitiligo or resolved childhood asthma/atopy would be exception to this rule.
T62	Not_a_criteria 1362 1466	Patients that require inhaled steroids or local steroid injections would not be excluded from the study.
T63	Condition 1481 1495	hypothyroidism
T64	Condition 1505 1523	autoimmune disease
T65	Negation 1496 1499	not
T66	Qualifier 1532 1561	stable on hormone replacement
T67	Procedure 1542 1561	hormone replacement
T68	Grammar_Error 1562 1597	will not be excluded from the study
T69	Not_a_criteria 1467 1598	Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study.
T70	Person 1600 1605	Women
T71	Condition 1614 1622	pregnant
T72	Condition 1626 1633	nursing
T73	Observation 1634 1647	breastfeeding
T74	Condition 1656 1689	hypersensitivity to pembrolizumab
T75	Drug 1676 1689	pembrolizumab
T76	Condition 1656 1675;1701 1704	hypersensitivity to mAb
T77	Drug 1701 1704	mAb
T78	Drug 1767 1775	steroids
T79	Condition 1787 1798	pneumonitis
T80	Temporal 1779 1786	current
T81	Condition 1741 1752	pneumonitis
T82	Temporal 1713 1720	history
T83	Qualifier 1758 1775	required steroids
T84	Condition 1825 1855	central nervous system disease
T85	Undefined_semantics 1825 1855	central nervous system disease
T86	Qualifier 1815 1824	untreated
T87	Condition 1890 1901	CNS lesions
T88	Procedure 1921 1928	surgery
T89	Procedure 1932 1957	stereotactic radiosurgery
T90	Temporal 1969 1980	for 4 weeks
T91	Qualifier 1962 1968	stable
T93	Qualifier 1871 1881	controlled
T94	Qualifier 1882 1889	treated
T95	Condition 1996 2050	Inability to comply with protocol required procedures.
T96	Undefined_semantics 1996 2050	Inability to comply with protocol required procedures.
T97	Non-query-able 1996 2050	Inability to comply with protocol required procedures.
T98	Post-eligibility 1996 2050	Inability to comply with protocol required procedures.
T99	Condition 2066 2084	medical conditions
T100	Procedure 2106 2137	systemic corticosteroid therapy
T101	Temporal 2098 2105	chronic
T102	Drug 2167 2195	immunosuppressive medication
T103	Undefined_semantics 2167 2195	immunosuppressive medication
T104	Qualifier 2090 2137	require chronic systemic corticosteroid therapy
T105	Qualifier 2141 2148;2167 2195	require immunosuppressive medication
T107	Multiplier 2221 2250	physiologic replacement doses
T108	Drug 2254 2268	hydrocortisone
T109	Drug 2345 2359	hydrocortisone
T110	Multiplier 2333 2344	up to 20 mg
T111	Drug 2372 2382	prednisone
T112	Multiplier 2364 2368	5 mg
T113	Drug 2409 2423	hydrocortisone
T114	Multiplier 2403 2408	10 mg
T115	Drug 2435 2445	prednisone
T116	Multiplier 2428 2434	2.5 mg
T117	Multiplier 2384 2398	in the morning
T118	Multiplier 2447 2461	in the evening
T121	Condition 2499 2516	bowel obstruction
T122	Condition 2520 2537	bowel perforation
T123	Condition 2482 2516	risk factors for bowel obstruction
T124	Condition 2482 2498;2520 2537	risk factors for bowel perforation
T125	Temporal 2577 2584	history
T126	Condition 2588 2608	acute diverticulitis
T127	Condition 2610 2633	intra-abdominal abscess
T128	Condition 2635 2659	abdominal carcinomatosis
T131	Drug 2692 2704	live vaccine
T132	Temporal 2705 2762	within 30 days prior to the first dose of trial treatment
T133	Reference_point 2729 2762	the first dose of trial treatment
